Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 8/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 4/20 | 0.35 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20009111 | 0.86 | PIK3CD (0.38) | PIK3CDHRH3ACACB | |
| SCHEMBL20008973 | 0.84 | PIK3CD (0.54) | PIK3CDHRH3GRM5ALDH1A1HSP90AA1 | |
| SCHEMBL21064695 | 0.84 | PIK3CD (0.48) | PIK3CDGRM5ALDH1A1GAAADORA2B | |
| SCHEMBL25872053 | 0.72 | POLB (0.34) | PIK3CDHRH3POLB | |
| SCHEMBL20009042 | 0.71 | PIK3CD (0.50) | PIK3CDHRH3GRM5ALDH1A1GAA | |
| SCHEMBL24448652 | 0.70 | PIK3CD (0.37) | PIK3CDHRH3POLB | |
| SCHEMBL26241331 | 0.69 | PIK3CD (0.51) | PIK3CDGRM5ALDH1A1GAAHSP90AA1 | |
| SCHEMBL25540243 | 0.69 | DPP4 (0.37) | HRH3POLB | |
| SCHEMBL19701901 | 0.68 | PIK3CD (1.00) | PIK3CDGRM5ALDH1A1HSP90AA1MAPT | |
| SCHEMBL19710934 | 0.68 | PIK3CD (0.65) | PIK3CDGRM5ALDH1A1GAAHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | PIK3CD 3161/4885HRH3 203/4885GRM5 1607/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | PIK3CD 3161/4885HRH3 203/4885GRM5 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.